Drugs / NY-ESO-1b.A2
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT00365937 | Aug 2006 → Dec 2013 | cutaneous melanoma | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NY-ESO-1b.A2 | “NY-ESO-1b.A2: lyophilized powder, 290 mcg, 5 injections every 3 weeks” NCT00365937 ↗ |
| Modality | Peptide | “The eight HLA-A2 peptides” NCT00365937 ↗ |